2023
AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers
Abu-Khalaf M, Alex Hodge K, Hatzis C, Baldelli E, El Gazzah E, Valdes F, Sikov W, Mita M, Denduluri N, Murphy R, Zelterman D, Liotta L, Dunetz B, Dunetz R, Petricoin E, Pierobon M. AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers. Npj Precision Oncology 2023, 7: 18. PMID: 36797347, PMCID: PMC9935518, DOI: 10.1038/s41698-023-00360-5.Peer-Reviewed Original ResearchEndocrine therapyProgressive diseaseCDK4/6 inhibitionImmune cellsTumor epitheliumOpen-label multicenter clinical trialMetastatic breast cancer patientsPI3K/AKT/mTOR activationFirst-line treatmentMetastatic breast cancerBreast cancer patientsAkt/mTOR activationMulticenter clinical trialAkt/mTORMBC patientsCancer patientsPredictive markerClinical trialsDisease progressionBreast cancerTreatment selectionTissue biopsiesPatientsNumber of FDAMTOR activation
1983
Differences in biological activity among batches of lyophilized tice Bacillus Calmette-Guérin and their association with clinical course in Stage I lung cancer.
Bennett J, Gruft H, McKneally M, Zelterman D, Crispen R. Differences in biological activity among batches of lyophilized tice Bacillus Calmette-Guérin and their association with clinical course in Stage I lung cancer. Cancer Research 1983, 43: 4183-90. PMID: 6347367.Peer-Reviewed Original ResearchConceptsBacillus Calmette-GuérinLung Cancer Study GroupCancer Study GroupTumor cellsCalmette-GuérinStudy groupNorth American Lung Cancer Study GroupStage I lung cancer patientsStage I lung cancerI lung cancerAntitumor activityDisease-free intervalProlongation of survivalLung cancer patientsFuture clinical trialsAdjuvant therapyClinical courseCancer patientsLung cancerClinical trialsSolid tumor growthTumor growthTumor colonizationPreclinical testingLethal dose